⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054226 | 1.00 | — | — | |
| SCHEMBL1052803 | 0.91 | NOS3 (0.31) | — | |
| SCHEMBL28216719 | 0.89 | NOS3 (0.30) | — | |
| SCHEMBL1539714 | 0.89 | — | — | |
| SCHEMBL5322531 | 0.87 | — | — | |
| SCHEMBL27987685 | 0.86 | — | — | |
| SCHEMBL28693358 | 0.86 | — | — | |
| SCHEMBL27988022 | 0.86 | — | — | |
| SCHEMBL28329693 | 0.84 | — | — | |
| SCHEMBL27330642 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3997104-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2022-05-18 | — | — | EP | disclosed |
| EP-3917509-A1 | TRANS-4-HYDROXYCYCLOHEXYL PHENYL AMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | Mitochondria Emotion, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-3917508-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | Mitochondria Emotion, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2021005131-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2021-01-14 | — | — | WO | disclosed |
| WO-2020159797-A1 | TRANS-4-HYDROXYCYCLOHEXYL PHENYL AMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MITOCHONDRIA EMOTION, INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020159576-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MITOCHONDRIA EMOTION, INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| EP-3468991-A1 | ANTI-GP73 ANTIBODIES AND IMMUNOCONJUGATES | cureab GmbH (CH) | 2019-04-17 | — | — | EP | disclosed |
| EP-3416634-A1 | IMMUNOMODULATORY AGENTS AND METHODS OF USE THEREOF | Artyomov, Maxim (US) | 2018-12-26 | — | — | EP | disclosed |
| WO-2018091724-A1 | ANTI-GP73 ANTIBODIES AND IMMUNOCONJUGATES | CUREAB GMBH (CH) | 2018-05-24 | — | — | WO | disclosed |
| WO-2017143014-A1 | JAK INHIBITORS AND USES THEREOF | KIM BRIAN (US) | 2017-08-24 | — | — | WO | disclosed |
| WO-2016005474-A1 | SITE SELECTIVE CONJUGATION OF AN OLIGONUCLEOTIDE CONJUGATE OR A SMALL MOLECULE TO A METAL BINDING PROTEIN | AFFYCON APS (DK) | 2016-01-14 | — | — | WO | disclosed |
| WO-2015112909-A1 | METHODS OF USING ANTI-STEAP1 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| WO-2015042108-A1 | METHODS OF USING ANTI-LGR5 ANTIBODIES | GENENTECH, INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| EP-2831118-A1 | ANTI-LGR5 ANTIBODIES AND IMMUNOCONJUGATES | Genentech, Inc. (US) | 2015-02-04 | — | — | EP | disclosed |
| WO-2013149159-A9 | ANTI-LGR5 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013149159-A1 | ANTI-LGR5 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2013-10-03 | — | — | WO | disclosed |
| EP-2637692-A2 | ANTIBODIES TO TUMOR ENDOTHELIAL MARKER 8 | Scott & White Healthcare (US) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012065161-A2 | ANTIBODIES TO TUMOR ENDOTHELIAL MARKER 8 | SCOTT & WHITE HEALTHCARE (US) | 2012-05-18 | — | — | WO | disclosed |
| EP-1912671-A2 | BETA-GLUCURONIDE-LINKER DRUG CONJUGATES | Seattle Genetics, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007011968-A2 | BETA-GLUCURONIDE-LINKER DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2007-01-25 | — | — | WO | disclosed |